Results 171 to 180 of about 182,500 (270)
This article discusses the emerging radiotherapy‐free and chemo‐free strategies in PD‐L1–high, unresectable stage III NSCLC, reviewing the Evolution trial and comparing it with existing treatments. We highlight the need for further research to validate these approaches and ensure safe de‐escalation without compromising ...
Yongbo Xiang, Nan Bi
wiley +1 more source
Synergistic antitumor effects of combined pembrolizumab and anlotinib via EGFR inhibition and tumor microenvironment remodeling in high-grade serous ovarian cancer. [PDF]
Yin X +10 more
europepmc +1 more source
Figure 1 Patient selection flowchart. CCRT, concurrent chemoradiotherapy; NCCRT, nimotuzumab and concurrent chemoradiotherapy. Abstract Purpose Patients with locally advanced head and neck squamous cell carcinoma (LA‐HNSCC) harboring high‐risk pathological features after radical surgery face high recurrence rates.
Yuejia Zhou +8 more
wiley +1 more source
In this study, mean lung dose (MLD) and age were associated with an increased risk of treatment‐related pneumonitis in patients receiving concurrent chemoradiotherapy and immunotherapy, providing a reference for revising lung dose constraints. Abstract Objective Combining immune checkpoint inhibitors (ICIs) with chemoradiotherapy is being actively ...
Ying Lu +9 more
wiley +1 more source
ABSTRACT Background Androgen receptor pathway inhibitors (ARPIs) such as abiraterone and enzalutamide are common therapies in the management of metastatic castration‐resistant prostate cancer (mCRPC). However, the comparative effectiveness of these oral ARPIs in frail and comorbid patient populations remains uncertain.
Meghana Yellanki +6 more
wiley +1 more source
Adjuvant therapy for RCC: considerations beyond survival metrics. [PDF]
Fribourg-Liendo RA, Yip W.
europepmc +1 more source
Abstract In oncology drug development, measuring drug concentrations at the tumor site and at the targeted receptor remains an ongoing challenge. Positron emission tomography (PET)‐imaging is a promising noninvasive method to quantify intratumor exposure of a radiolabeled drug (biodistribution data) and target saturation by treatment doses in vivo ...
Robin Michelet +8 more
wiley +1 more source
Navigating the current and future perioperative treatment landscape of muscle-invasive bladder cancer (MIBC). [PDF]
Azad F, Kevu E, Aragon-Ching JB.
europepmc +1 more source
Mechanistic Learning for Predicting Survival Outcomes in Head and Neck Squamous Cell Carcinoma
ABSTRACT We employed a mechanistic learning approach, integrating on‐treatment tumor kinetics (TK) modeling with various machine learning (ML) models to address the challenge of predicting post‐progression survival (PPS)—the duration from the time of documented disease progression to death—and overall survival (OS) in Head and Neck Squamous Cell ...
Kevin Atsou +4 more
wiley +1 more source
A Phase II Trial of Pembrolizumab plus Granulocyte-Macrophage Colony-Stimulating Factor in Advanced Biliary Cancer. [PDF]
Kelley RK +13 more
europepmc +1 more source

